COMMENTARY

Generic Industry’s Tactic to Thwart 50% Pricing Rule Draws Mixed Reviews

January 18, 2016

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The tactic selected by the Japan Generic Medicines Association (JGA) to prevent the government from introducing a 50% pricing rule for first generics has received mixed reactions from health ministry bureaucrats and industry insiders. Some at the Ministry of Health,…

To read the full story

JGA Takes Sincerely 50% Pricing Rule for First Generics, There’s Limitation to Data Collection: Chief
January 13, 2016

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze
June 16, 2026
20 Years at a Glance: Overseas Sales Surge at Japan Pharma, but R&D Investments Lag
June 9, 2026
Are Technical Discussions Enough for Japan’s CEA System?
May 25, 2026
Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises
April 28, 2026
Gene Therapies Expand into AMD, Raising Promise and Cost Concerns
April 24, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…